Weng TC, et al. J Clin Pharm Ther 2010;35:139-51.

Slides:

Advertisements

Similar presentations

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

Advertisements

Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.

* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.

Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Baseline characteristics of HPS participants by prior cerebrovascular disease.

Parameters BD PP CP TC (mg. dl-l) ± * ± 5.8

Dyslipidemia and Diabetic Macular Edema

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Arch Intern Med. 2004;164(7): doi: /archinte Figure Legend:

Krill oil supplementation lowers serum triglycerides without increasing low-density lipoprotein cholesterol in adults with borderline high or high triglyceride.

Copyright © 2011 American Medical Association. All rights reserved.

Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.

LIPID PROFILE OF EARLY RHEUMATOID ARTHRITIS PATIENTS

Statin Myopathy (AHA/ACC/NHLBI)

First time a CETP inhibitor shows reduction of serious CV events

Copyright © 2012 American Medical Association. All rights reserved.

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Oxford Niacin Trial.

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis? Sripal Bangalore, MD,

Omega-3 Fatty Acids for Cardioprotection

Effect of evolocumab on lipoprotein particles

TNT Study: Baseline Characteristics of the Patients

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Description of studies for pooled analyses

Task-sharing interventions for cardiovascular risk reduction and lipid outcomes in low- and middle-income countries: A systematic review and meta-analysis

Efficacy and safety of niacin/laropiprant

Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:

Classification of statins/dosages according to the attainable

Potential mechanisms whereby statins may reduce the risk of stroke

Comparison of clinical and functional parameters among non-responders (=1) and responders (≥4) among healthy elderly and elderly patients with T2DM. Comparison.

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Berger JS, et al. JAMA 2009;301:

Flow of Patients Through the Trial

Flow of Patients Through Trial

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

New Lipid-Lowering Therapies

Study Participant Flow

Baseline Patients with coronary artery disease (CAD) and high (n=98) versus normal (n=1512) high-density lipoprotein (HDL) levels Doreen DeFaria Yeh, et.

Comparison of clinical and functional parameters between the CMV+ and CMV− participants in the healthy elderly and elderly patients with T2DM. Comparison.

Baseline Characteristics of the Subjects*

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Study Flow Diagram Thompson A, et al. JAMA 2008;299:

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Characteristics of included studies

Receiver operating curves (ROC) of simple age and gender adjusted risk factor models for predicting 10-year risk of cardiovascular disease comparing the.

RADIANCE 2 Study: Trial proﬁle

Lars E. Laugsand et al. BTS 2016;j.jacbts

Titration activities from baseline up to 6 and 12 months follow-up in nurse-coordinated care (NCC) versus usual care patients. X-as: patients (percentage),

The ACCORD Study Group. NEJM 2010; Epub March 14

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

Change in markers of glycometabolism and cardiovascular risk profile.

Association between statin dose and 1-year admission to hospital for cardiovascular events in older Ontario residents living in long-term care facilities.

Amir A. Mahabadi et al. JIMG 2017;10:

Flow of study participants

Increase of physical activity over time associated with lower HF risk

in diabetic patients with mixed dyslipidemia

Individual lipid measures for high-carbohydrate (n=10) and low-carbohydrate (n=10) ultra-endurance athletes. Individual lipid measures for high-carbohydrate.

LDL-c reductions below 1

International Journal of Cardiology

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Medication intensity (ALLP) changes between baseline and 6 months, by (not) being low-density lipoprotein-cholesterol (LDL-C) target at baseline for nurse-coordinated.

Presentation transcript:

Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Baseline characteristics of statin studies with paired-comparisons Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Comparisons of the lipid lowering effect of different statins: LDL Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Comparisons of the lipid lowering effect of different statins: HDL Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Comparisons of the lipid lowering effect of different statins: TG Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Low density lipoprotein (LDL) reduction (%) of different statins in different doses Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Weighted mean difference (WMD) with 95% confidence interval (CI) of different statins at equivalent dose Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Effects on cardiovascular events Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Incidence of specific adverse effects (%) Weng TC, et al. J Clin Pharm Ther 2010;35:139-51

Flow chart of the article selection Weng TC, et al. J Clin Pharm Ther 2010;35:139-51